首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

市場調查報告書

商品編碼

1676206

全球大分子藥物 CDMO 市場研究報告 - 產業分析、規模、佔有率、成長、趨勢和預測 2025 年至 2033 年

Global Large Molecule Drug Substance CDMO Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年03月01日 | 出版商:

Value Market Research | 英文 157 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球大分子藥物 Cdmo 市場規模預計將從 2024 年的 208.2 億美元成長到 2033 年的 485.8 億美元，在 2026 年至 2033 年的預測期內呈現 9.87% 的強勁年複合成長率(CAGR)。

隨著生物製劑的日益複雜以及對創新療法的需求不斷成長，大分子藥物合約開發和製造組織 (CDMO) 市場即將大幅擴張。隨著製藥公司轉向生物製劑，對專業製造能力的需求變得至關重要。該市場的特點是從傳統的小分子藥物轉向大分子治療劑，包括單株抗體、重組蛋白和基因療法。這些產品的複雜性質需要先進的製造流程、嚴格的品質控制和法規遵循性，而 CDMO 具有獨特的優勢來提供這些服務。

此外，個人化醫療的興起正在催化對客製化生物療法的需求，進一步推動大分子藥物 CDMO 市場的成長。隨著醫療保健系統擴大採用精準醫療方法，大規模生產客製化生物製劑的能力將成為製藥公司的關鍵差異化因素。投資於一次性系統和持續製造等尖端技術的 CDMO 可能會獲得競爭優勢。此外，生物製藥公司和 CDMO 之間的策略合作夥伴關係將增強創新並加快新療法的開發，確保市場保持活力並響應新興的醫療保健需求。

大分子藥物 CDMO 的全球格局也受到監管進步和對永續性日益關注的影響。隨著監管機構簡化生物製劑的核准流程，新療法的上市時間將會縮短，為 CDMO 創造更靈活的環境。此外，在製造過程中融入永續實踐不僅可以滿足監管要求，而且還能滿足消費者對環保醫療保健解決方案日益成長的需求。隨著市場的發展，重視創新、協作和永續性的 CDMO 將在這個新興領域佔據有利地位並蓬勃發展。

我們的報告經過精心製作，為客戶提供有關各個行業和市場的全面且可操作的見解。每份報告都包含幾個關鍵部分，以確保徹底了解市場格局：

市場概覽：市場的詳細介紹，包括定義、分類和行業現狀概述。

市場動態：深入分析影響市場成長的關鍵促進因素、限制因素、機會與挑戰。本節探討技術進步、監管變化和新興趨勢等因素。

細分分析：根據產品類型、應用、最終用戶和地理位置等標準將市場細分為不同的細分市場。該分析強調了每個部分的表現和潛力。

競爭格局：對主要市場參與者的全面評估，包括其市場佔有率、產品組合、策略舉措和財務表現。本節深入介紹領先公司的競爭動態和關鍵策略。

市場預測：根據歷史資料和當前市場狀況，預測特定時期內的市場規模和成長趨勢。這包括定量分析和圖形表示來說明未來的市場軌跡。

區域分析：評估不同地理區域的市場表現，確定關鍵市場和區域趨勢。這有助於了解區域市場動態和機會。

新興趨勢與機會：識別當前和新興的市場趨勢、技術創新和潛在投資領域。本節提供未來市場發展和成長前景的見解。

區域展望
介紹
北美銷售分析
- 概述、歷史和預測數據銷售分析
- 北美各細分市場銷售分析
- 北美各國銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測數據銷售分析
- 歐洲各細分市場銷售分析
- 歐洲各國銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測數據銷售分析
- 亞太地區分部銷售分析
- 亞太地區國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測數據銷售分析
- 拉丁美洲各細分市場銷售分析
- 拉丁美洲各國銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測數據銷售分析
- 中東和非洲分部銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東和非洲其他地區銷售分析

第 9 章：大分子藥物 CDMO 公司的競爭格局

大分子藥物CDMO市場競爭
夥伴關係/合作/協議
合併與收購
新產品發布
其他進展

第10章：公司簡介

頂級公司市佔率分析
市場集中度
Eurofins Scientific

公司概況
公司收入
產品
最新動態

WuXi Biologics

公司概況
公司收入
產品
最新動態

Samsung Biologics

公司概況
公司收入
產品
最新動態

Catalent Inc.

公司概況
公司收入
產品
最新動態

Rentschler Biopharma SE

公司概況
公司收入
產品
最新動態

AGC Biologics

公司概況
公司收入
產品
最新動態

Recipharm AB

公司概況
公司收入
產品
最新動態

Siegfried Holding AG

公司概況
公司收入
產品
最新動態

Boehringer Ingelheim

公司概況
公司收入
產品
最新動態

FUJIFILM Diosynth Biotechnologies

公司概況
公司收入
產品
最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，對於私人公司，可能不予涵蓋

簡介目錄圖表

Product Code: VMR112110346

Global Large Molecule Drug Substance Cdmo Market size is anticipated to grow from USD 20.82 Billion in 2024 to USD 48.58 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 9.87% during the forecast period of 2026 to 2033.

The Large Molecule Drug Substance Contract Development and Manufacturing Organization (CDMO) market is poised for significant expansion, driven by the increasing complexity of biologics and the growing demand for innovative therapies. As pharmaceutical companies pivot towards biologics, the need for specialized manufacturing capabilities becomes paramount. This market is characterized by a shift from traditional small-molecule drugs to large-molecule therapeutics, including monoclonal antibodies, recombinant proteins, and gene therapies. The intricate nature of these products necessitates advanced manufacturing processes, stringent quality control, and regulatory compliance, which CDMOs are uniquely positioned to provide.

Moreover, the rise of personalized medicine is catalyzing the demand for tailored biologic therapies, further propelling the growth of the Large Molecule Drug Substance CDMO market. As healthcare systems increasingly adopt precision medicine approaches, the ability to produce customized biologics at scale will be a critical differentiator for pharmaceutical companies. CDMOs that invest in cutting-edge technologies, such as single-use systems and continuous manufacturing, will likely gain a competitive edge. Additionally, strategic partnerships between biopharmaceutical companies and CDMOs will enhance innovation and expedite the development of novel therapies, ensuring that the market remains dynamic and responsive to emerging healthcare needs.

The global landscape for Large Molecule Drug Substance CDMOs is also influenced by regulatory advancements and the increasing focus on sustainability. As regulatory bodies streamline approval processes for biologics, the time-to-market for new therapies will decrease, fostering a more agile environment for CDMOs. Furthermore, the integration of sustainable practices in manufacturing processes will not only meet regulatory requirements but also align with the growing consumer demand for environmentally responsible healthcare solutions. As the market evolves, CDMOs that prioritize innovation, collaboration, and sustainability will be well-positioned to thrive in this burgeoning sector.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Service

Contract Manufacturing
Contract Development

By Source

Mammalian
Microbial
Others

By End-User

Biotech Companies
CRO
Other
COMPANIES PROFILED
Eurofins Scientific
WuXi Biologics
Samsung Biologics
Catalent Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
Boehringer Ingelheim
FUJIFILM Diosynth Biotechnologies
The above list can be customized.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porters Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Service
- 3.7.2 Market Attractiveness Analysis By Source
- 3.7.3 Market Attractiveness Analysis By End-User
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SERVICE

5.1. Overview By Service
5.2. Historical and Forecast Data Analysis By Service
5.3. Contract Manufacturing Historic and Forecast Sales By Regions
5.4. Contract Development Historic and Forecast Sales By Regions

6. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SOURCE

6.1. Overview By Source
6.2. Historical and Forecast Data Analysis By Source
6.3. Mammalian Historic and Forecast Sales By Regions
6.4. Microbial Historic and Forecast Sales By Regions
6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY END-USER

7.1. Overview By End-User
7.2. Historical and Forecast Data Analysis By End-User
7.3. Biotech Companies Historic and Forecast Sales By Regions
7.4. CRO Historic and Forecast Sales By Regions
7.5. Other Historic and Forecast Sales By Regions

8. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE LARGE MOLECULE DRUG SUBSTANCE CDMO COMPANIES

9.1. Large Molecule Drug Substance CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Eurofins Scientific
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. WuXi Biologics
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Samsung Biologics
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Catalent Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Rentschler Biopharma SE
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. AGC Biologics
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Recipharm AB
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Siegfried Holding AG
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Boehringer Ingelheim
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. FUJIFILM Diosynth Biotechnologies
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Service (USD MN)
Contract Manufacturing Market Sales By Geography (USD MN)
Contract Development Market Sales By Geography (USD MN)
Analysis By Source (USD MN)
Mammalian Market Sales By Geography (USD MN)
Microbial Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By End-User (USD MN)
Biotech Companies Market Sales By Geography (USD MN)
CRO Market Sales By Geography (USD MN)
Other Market Sales By Geography (USD MN)
Global Large Molecule Drug Substance CDMO Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Large Molecule Drug Substance CDMO Report
Market Research Process
Market Research Methodology
Global Large Molecule Drug Substance CDMO Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Service
Market Attractiveness Analysis By Source
Market Attractiveness Analysis By End-User
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Service (USD MN)
Contract Manufacturing Market Sales By Geography (USD MN)
Contract Development Market Sales By Geography (USD MN)
Global Market Analysis By Source (USD MN)
Mammalian Market Sales By Geography (USD MN)
Microbial Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By End-User (USD MN)
Biotech Companies Market Sales By Geography (USD MN)
CRO Market Sales By Geography (USD MN)
Other Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.